查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601121

核子醫學市場：按產品、應用、類型和最終用戶 - 2025-2030 年全球預測

Nuclear Medicine Market by Product (Diagnostic Products, Therapeutic Products), Application (Bone Metastasis, Cardiology, Endocrine Tumor), Type, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年核醫市場價值為51.4億美元，預計2024年將達到55.1億美元，複合年成長率為7.35%，到2030年將達到84.5億美元。

核子醫學是一門醫學影像專業，它使用少量的放射性物質（稱為放射性藥物）來診斷和治療各種疾病，包括癌症、心臟病和神經系統疾病。對核子醫學的需求源於其能夠提供對器官和組織生理功能的獨特見解，從而實現早期診斷和量身定做的治療計劃。 PET和SPECT掃描等技術用於準確的疾病檢測，放射性同位素療法用於治療。最終用途範圍從醫院和診所到診斷中心和研究機構。推動核醫學市場的主要成長要素包括成像技術的技術進步、慢性病的流行以及對早期診斷益處的認知不斷提高。此外，個人化醫療的日益普及和新型放射性藥物的開發提供了巨大的潛在機會。為了抓住這些機會，產業參與者應投資創新的放射性同位素研發，並專注於利用人工智慧來改善成像結果和患者治療結果。然而，挑戰包括高昂的設備成本、嚴格的監管要求以及某些放射性同位素的供應有限，這可能會限制市場成長。非侵入性顯像模式的開發和新的治療診斷應用等創新被認為是克服這些挑戰的有希望的途徑。該市場競爭激烈且充滿活力，其特點是研究機構和醫療保健提供者之間不斷進步和策略聯盟。公司可以透過專注於新興市場、解決供應鏈問題並確保遵守監管標準來獲得真正的優勢。這些策略舉措對於在市場格局中持續取得成功和保持領導地位至關重要，因為市場存在取決於對技術和監管條件變化快速反應的能力。

主要市場統計
基準年[2023] 51.4億美元
預測年份 [2024] 55.1億美元
預測年份 [2030] 84.5億美元
複合年成長率（%） 7.35%

市場動態：揭示快速發展的核子醫學市場的關鍵市場洞察

供需的動態交互作用正在改變核醫市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球癌症發生率和盛行率不斷上升
    • 擴大使用 PET 和 SPECT 來診斷心臟和神經系統疾病
    • 國際組織支持核子醫學的努力和意識提升
  • 市場限制因素
    • 核醫學半衰期短
  • 市場機會
    • 治療診斷學在核子醫學中日益普及
    • 持續的產品開發和專利技術進步
  • 市場挑戰
    • 新興國家缺乏核醫學知識、培訓和可得性
    • 全球缺乏熟練的放射科醫生和專家

波特五力：駕馭核醫市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解核子醫學市場的外部影響

外部宏觀環境因素在塑造核醫市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解核子醫學市場的競爭狀況

對核子醫學市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣核子醫學市場供應商的績效評估

FPNV定位矩陣是評估核子醫學市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的癌症發生率和盛行率正在上升
      • PET 和 SPECT 在診斷心臟和神經系統疾病的使用增加
      • 國際組織的努力與支持核子醫學的認知
    • 抑制因素
      • 核醫學半衰期短
    • 機會
      • 治療診斷學在核子醫學中日益普及
      • 持續的產品開發和專利技術進步
    • 任務
      • 新興國家缺乏核子醫學知識、培訓和可用性
      • 全球缺乏熟練的放射科醫生和醫生
  • 市場區隔分析
    • 產品：診斷產品在核子醫學的意義
    • 最終用戶：醫院和診斷中心的各種應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章核子醫學市場：依產品

  • 診斷產品
    • PET
      • F-18
      • SR-82/RB-82
    • SPECT
      • GA-67
      • I-123
      • TC-99m
      • TL-201
  • 治療產品
    • α發射體
    • BETA放射體
      • I-131
      • Lu-117
      • 重新 186
      • SM-153
      • Y-90
    • 放射線治療
      • 銫131
      • 碘125
      • 銥192
      • 鈀103

第7章 核子醫學市場：依應用分類

  • 骨轉移
  • 心臟病學
  • 內分泌腫瘤
  • 淋巴瘤
  • 腫瘤學
  • 甲狀腺

第8章核子醫學市場：依類型

  • 診斷
    • PET檢查
    • SPECT程式
  • 治療性的
    • α發射體
    • BETA發射器程式
    • 放射線治療程序

第9章核醫市場：依最終使用者分類

  • 醫院和診斷中心
  • 調查機構

第10章美洲核子醫學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太核子醫學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲核子醫學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Shine 與 Nucleus RadioPharma 簽署供應協議
    • ITM 與加拿大核能研究所組成新公司
    • Life Healthcare 將收購南非核子醫學業務

公司名單

  • Actinium Pharmaceuticals, Inc.
  • Bayer AG
  • BJ Madan & Co.
  • Bracco SpA
  • BWX Technologies, Inc. by Framatome
  • Cardinal Health, Inc.
  • Curium
  • Eckert & Ziegler Radiopharma GmbH
  • Eczacibasi Monrol Nuclear Products Co.
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Institute of Isotopes Co., Ltd.
  • Isotope Joint Stock Company
  • Isotopia Molecular Imaging
  • Jubilant DraxImage, Inc.
  • Lantheus Holdings, Inc.
  • Nordic Nanovector ASA by Thor Medical
  • Nordion（Canada）Inc. by Sotera Health LLC
  • Northstar Medical Technologies LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • PharmaLogic Holdings LLC
  • Radiopharm Theranostics Limited
  • SHINE Technologies, LLC
  • Sinotau Pharmaceuticals Group
Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market was valued at USD 5.14 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 7.35%, to USD 8.45 billion by 2030.

Nuclear medicine is a specialized area of medical imaging that uses small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat various diseases, including cancer, heart disease, and neurological disorders. The necessity of nuclear medicine arises from its ability to provide unique insights into the physiological function of organs and tissues, thus enabling earlier diagnosis and tailored treatment plans. Applications span diagnostic and therapeutic uses, where techniques like PET and SPECT scans are employed for precise disease detection, and radioisotope therapy is utilized in treatments. The end-use scope ranges from hospitals and clinics to diagnostic centers and research institutions. Key growth factors driving the nuclear medicine market include technological advancements in imaging techniques, a growing prevalence of chronic diseases, and increased awareness of the benefits of early diagnosis. Furthermore, increasing adoption of personalized medicine and the development of novel radiopharmaceuticals present significant potential opportunities. To capture these opportunities, industry players should focus on investing in R&D for innovative radioisotopes and leveraging AI to enhance imaging results and patient outcomes. However, challenges lie in the high cost of equipment, stringent regulatory requirements, and limited availability of certain radioisotopes, which can constrain market growth. Innovations, such as developing non-invasive imaging modalities and new theranostic applications, are seen as promising avenues for overcoming these challenges. The market is competitive and dynamic, characterized by continuous advancements and strategic collaborations among research institutions and healthcare providers. Companies can gain a substantial edge by focusing on emerging markets, addressing supply chain issues, and ensuring compliance with regulatory standards. Such strategic moves are essential for sustained success and leadership in the nuclear medicine landscape, where the ability to promptly adapt to technological and regulatory changes can define market presence.

KEY MARKET STATISTICS
Base Year [2023] USD 5.14 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 8.45 billion
CAGR (%) 7.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nuclear Medicine Market

The Nuclear Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Incidence and Prevalence of Cancer Worldwide
    • Increasing Use of PET and SPECT to Diagnose Heart disease and Neurological Disorders
    • International Organizations' Initiatives and Awareness Supporting Nuclear Medicine
  • Market Restraints
    • Shorter Half-Life of Nuclear Medicine
  • Market Opportunities
    • Emerging Popularity of Theranostics in Nuclear Medicine
    • Continuous Product Developments and Advancements in Patented Technologies
  • Market Challenges
    • Lack of Knowledge, Training, and Availability of Nuclear Medicine in Developing Countries
    • Limited Availability of Skilled Radiologists and Practitioners Worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Nuclear Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nuclear Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nuclear Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nuclear Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nuclear Medicine Market

A detailed market share analysis in the Nuclear Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nuclear Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nuclear Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Nuclear Medicine Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Bayer AG, BJ Madan & Co., Bracco S.p.A., BWX Technologies, Inc. by Framatome, Cardinal Health, Inc., Curium, Eckert & Ziegler Radiopharma GmbH, Eczacibasi Monrol Nuclear Products Co., GE Healthcare, IBA Radiopharma Solutions, Institute of Isotopes Co., Ltd., Isotope Joint Stock Company, Isotopia Molecular Imaging, Jubilant DraxImage, Inc., Lantheus Holdings, Inc., Nordic Nanovector ASA by Thor Medical, Nordion (Canada) Inc. by Sotera Health LLC, Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., PharmaLogic Holdings LLC, Radiopharm Theranostics Limited, SHINE Technologies, LLC, and Sinotau Pharmaceuticals Group.

Market Segmentation & Coverage

This research report categorizes the Nuclear Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnostic Products and Therapeutic Products. The Diagnostic Products is further studied across PET and SPECT. The PET is further studied across F-18 and SR-82/RB-82. The SPECT is further studied across GA-67, I-123, TC-99m, and TL-201. The Therapeutic Products is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy. The Beta Emitters is further studied across I-131, Lu-117, Re-186, SM-153, and Y-90. The Brachytherapy is further studied across Cesium-131, Iodine-125, Iridium-192, and Palladium-103.
  • Based on Application, market is studied across Bone Metastasis, Cardiology, Endocrine Tumor, Lymphoma, Oncology, and Thyroid.
  • Based on Type, market is studied across Diagnostic and Therapeutic. The Diagnostic is further studied across PET Procedures and SPECT Procedures. The Therapeutic is further studied across Alpha Emitter Procedures, Beta Emitter Procedures, and Brachytherapy Procedures.
  • Based on End-Users, market is studied across Hospitals & Diagnostic Centers and Research institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Incidence and Prevalence of Cancer Worldwide
      • 5.1.1.2. Increasing Use of PET and SPECT to Diagnose Heart disease and Neurological Disorders
      • 5.1.1.3. International Organizations' Initiatives and Awareness Supporting Nuclear Medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Shorter Half-Life of Nuclear Medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging Popularity of Theranostics in Nuclear Medicine
      • 5.1.3.2. Continuous Product Developments and Advancements in Patented Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Knowledge, Training, and Availability of Nuclear Medicine in Developing Countries
      • 5.1.4.2. Limited Availability of Skilled Radiologists and Practitioners Worldwide
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significance of diagnostic products in nuclear medicines
    • 5.2.2. End-Users: Diverse applications in hospitals and diagnostic centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Nuclear Medicine Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostic Products
    • 6.2.1. PET
      • 6.2.1.1. F-18
      • 6.2.1.2. SR-82/RB-82
    • 6.2.2. SPECT
      • 6.2.2.1. GA-67
      • 6.2.2.2. I-123
      • 6.2.2.3. TC-99m
      • 6.2.2.4. TL-201
  • 6.3. Therapeutic Products
    • 6.3.1. Alpha Emitters
    • 6.3.2. Beta Emitters
      • 6.3.2.1. I-131
      • 6.3.2.2. Lu-117
      • 6.3.2.3. Re-186
      • 6.3.2.4. SM-153
      • 6.3.2.5. Y-90
    • 6.3.3. Brachytherapy
      • 6.3.3.1. Cesium-131
      • 6.3.3.2. Iodine-125
      • 6.3.3.3. Iridium-192
      • 6.3.3.4. Palladium-103

7. Nuclear Medicine Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Metastasis
  • 7.3. Cardiology
  • 7.4. Endocrine Tumor
  • 7.5. Lymphoma
  • 7.6. Oncology
  • 7.7. Thyroid

8. Nuclear Medicine Market, by Type

  • 8.1. Introduction
  • 8.2. Diagnostic
    • 8.2.1. PET Procedures
    • 8.2.2. SPECT Procedures
  • 8.3. Therapeutic
    • 8.3.1. Alpha Emitter Procedures
    • 8.3.2. Beta Emitter Procedures
    • 8.3.3. Brachytherapy Procedures

9. Nuclear Medicine Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals & Diagnostic Centers
  • 9.3. Research institutes

10. Americas Nuclear Medicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nuclear Medicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nuclear Medicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Shine Reaches Supply Agreement with Nucleus RadioPharma
    • 13.3.2. ITM and Canadian Nuclear Labs Launch New Company
    • 13.3.3. Life Healthcare Set to Acquire Nuclear-medicine Operation in SA

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Bayer AG
  • 3. BJ Madan & Co.
  • 4. Bracco S.p.A.
  • 5. BWX Technologies, Inc. by Framatome
  • 6. Cardinal Health, Inc.
  • 7. Curium
  • 8. Eckert & Ziegler Radiopharma GmbH
  • 9. Eczacibasi Monrol Nuclear Products Co.
  • 10. GE Healthcare
  • 11. IBA Radiopharma Solutions
  • 12. Institute of Isotopes Co., Ltd.
  • 13. Isotope Joint Stock Company
  • 14. Isotopia Molecular Imaging
  • 15. Jubilant DraxImage, Inc.
  • 16. Lantheus Holdings, Inc.
  • 17. Nordic Nanovector ASA by Thor Medical
  • 18. Nordion (Canada) Inc. by Sotera Health LLC
  • 19. Northstar Medical Technologies LLC
  • 20. Novartis AG
  • 21. NTP Radioisotopes SOC Ltd.
  • 22. PharmaLogic Holdings LLC
  • 23. Radiopharm Theranostics Limited
  • 24. SHINE Technologies, LLC
  • 25. Sinotau Pharmaceuticals Group

LIST OF FIGURES

  • FIGURE 1. NUCLEAR MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. NUCLEAR MEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NUCLEAR MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEAR MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY F-18, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SR-82/RB-82, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GA-67, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY I-123, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TC-99M, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TL-201, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY I-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY LU-117, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RE-186, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SM-153, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY Y-90, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINE TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THYROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 311. DENMARK NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 322. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 323. EGYPT NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 334. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 335. FINLAND NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 343. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 344. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 346. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 347. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 348. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 355. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 356. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 358. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 359. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 360. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 361. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 362. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2030 (USD MILLION)
  • TABLE 363. ISRAEL NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2030 (USD MILLION)
  • TABLE 364. ISRAEL NUCLEAR MEDICINE MARKET SIZE